| **Characteristic** | **No. (%)** |
| --- | --- |
| **Total population** | 11 (100) |
| Mean age, y | 65.5 |
| Sex (%) |   |
| Male | 4 (36.4) |
| Female | 7 (63.6) |
| Primary cancer diagnosis (%) |   |
|  Breast | 2 (18.2) |
|  Gastrointestinal | 3 (27.3) |
|  Lung | 1 (9.1) |
|  Genitourinary | 0 (0) |
|  Gynecologic | 1 (9.1) |
|  Head and neck | 3 (27.3) |
|  Others | 1 (9.1) |
| Stage (%) |  |
|  II | 3 (27.3) |
|  III | 3 (27.3) |
|  IV | 5 (45.4) |
| Stage at the beginning of the study (%) |   |
|  Local | 6 (54.5) |
|  Metastatic |  5 (45.5) |
| Stage at the time of third vaccine dose (%) |   |
|  Local | 2 (18.2) |
|  Metastatic | 9 (81.8) |
| Assessment of treatment response at the time of third vaccine dose (%)  |   |
|  No evidence of disease | 2 (18.2) |
|  Complete response | 2 (18.2) |
|  Stable disease | 0 (0) |
|  Partial response | 2 (18.2) |
|  Progressive disease | 5 (45.5) |
| Treatment (%) |   |
| Chemotherapy | 4 (36.4) |
| Immunotherapy | 2 (18.2) |
| Targeted therapy | 1 (9.1) |
| Chemotherapy plus targeted therapy | 3 (27.3) |
| Chemotherapy plus immunotherapy | 1 (9.1) |
| Immunotherapy plus targeted therapy | 0 (0) |
| Chemotherapy plus Immunotherapy plus targeted therapy  | 0 (0) |
| Heavily treated (three or more lines of treatment) at the time of third vaccine dose (%) |   |
| Yes | 4 (36.4) |
| No | 7 (63.6) |
| Prior/concomitant Radiotherapy (%) |   |
| Yes | 4 (36.4) |
| No | 7 (63.6) |
| Prior COVID-19 infection (%) |   |
| Yes | 0 (0) |
| No | 11 (100) |

**Supplementary Table 4.** Group 2 patients characteristics at third dose administration.